HC Wainwright Expects Higher Earnings for Verve Therapeutics

Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) - Research analysts at HC Wainwright increased their FY2025 EPS estimates for Verve Therapeutics in a report released on Monday, May 19th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of ($2.16) per share for the year, up from their previous estimate of ($2.38). HC Wainwright has a "Buy" rating and a $25.00 price objective on the stock. The consensus estimate for Verve Therapeutics' current full-year earnings is ($2.49) per share. HC Wainwright also issued estimates for Verve Therapeutics' Q1 2026 earnings at ($0.61) EPS, Q2 2026 earnings at ($0.66) EPS, Q3 2026 earnings at ($0.68) EPS and Q4 2026 earnings at ($0.70) EPS.

VERV has been the subject of a number of other research reports. Guggenheim upped their price target on Verve Therapeutics from $18.00 to $24.00 and gave the company a "buy" rating in a research report on Tuesday, April 15th. Wall Street Zen upgraded Verve Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday. Royal Bank of Canada cut their price target on shares of Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating on the stock in a report on Tuesday, March 4th. Canaccord Genuity Group lifted their price objective on Verve Therapeutics from $32.00 to $39.00 and gave the stock a "buy" rating in a report on Tuesday, April 15th. Finally, William Blair reissued an "outperform" rating on shares of Verve Therapeutics in a report on Friday, February 21st. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $25.75.

Verve Therapeutics Price Performance

Verve Therapeutics stock traded down $0.02 during trading hours on Wednesday, reaching $4.36. The company had a trading volume of 1,383,381 shares, compared to its average volume of 1,859,907. The company has a 50-day moving average price of $4.61 and a 200 day moving average price of $5.81. Verve Therapeutics has a 12-month low of $2.86 and a 12-month high of $9.31. The firm has a market cap of $388.66 million, a price-to-earnings ratio of -1.77 and a beta of 1.82.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.35) EPS for the quarter, topping analysts' consensus estimates of ($0.71) by $0.36. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. The firm had revenue of $32.98 million for the quarter, compared to analyst estimates of $7.13 million.

Hedge Funds Weigh In On Verve Therapeutics

Institutional investors have recently bought and sold shares of the business. IFP Advisors Inc lifted its holdings in shares of Verve Therapeutics by 823,700.0% during the 4th quarter. IFP Advisors Inc now owns 8,238 shares of the company's stock valued at $47,000 after purchasing an additional 8,237 shares during the last quarter. BNP Paribas Financial Markets acquired a new stake in Verve Therapeutics during the 4th quarter valued at approximately $50,000. KFG Wealth Management LLC acquired a new stake in shares of Verve Therapeutics in the first quarter worth $46,000. Cambridge Investment Research Advisors Inc. purchased a new position in shares of Verve Therapeutics during the 1st quarter valued at about $47,000. Finally, E Fund Management Co. Ltd. purchased a new stake in Verve Therapeutics in the 1st quarter worth approximately $48,000. 97.11% of the stock is owned by hedge funds and other institutional investors.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.